Swertisin

Swertisin at a Glance

Swertisin is a flavone C-glycoside — structurally 6-C-glucosyl-7-O-methylapigenin, i.e. the 7-O-methyl ether of isovitexin and a methylated, C-glucosylated relative of apigenin. It occurs in the bitter Gentianaceae (Swertia, Enicostemma) and in jujube (Ziziphus) seed, where it is the deglycosylation product of the sedative glycoside spinosin.

Its best-developed research thread is antidiabetic: an unusually specific signal that swertisin can push pancreatic stem/progenitor cells to differentiate into insulin-producing islet cells — a beta-cell regeneration story rather than a simple glucose-lowering one ^{1,2,3Reference 1Dadheech N et al. · 2015Swertisin an anti-diabetic compound facilitate islet neogenesis from pancreatic stem/progenitor cells via p-38 MAP kinase-SMAD pathway: an in-vitro and in-vivo studyView study →Reference 2Srivastava A et al. · 2018AnimalSwertisin ameliorates diabetes by triggering pancreatic progenitors for islet neogenesis in streptozotocin treated BALB/c miceView study →Reference 3Srivastava A et al. · 2019AnimalPancreatic resident endocrine progenitors demonstrate high islet neogenic fidelity and committed homing towards diabetic mice pancreasView study →}. That evidence is real but entirely preclinical (cell culture and rodents), and it sits alongside thinner neurocognitive, antiviral and anti-inflammatory reports. There are no human trials of the isolated molecule, and its pharmacokinetics are barely characterised. The literature is modest; the account stays lean and flags where it thins out.

Swertisin as a C-Glycoside

The single most important structural fact about swertisin is that its sugar is attached through a carbon–carbon bond (6-C-glucoside), not the more common oxygen bridge of an O-glycoside. This is not a chemical footnote — it changes what happens to the molecule in the gut.

Mammalian and bacterial glycosidases hydrolyse O-glycosides readily (cleaving the sugar to release the aglycone), but they cannot cleave a C–C glycosidic bond. So a C-glycoside such as swertisin tends to survive intestinal digestion intact, circulating as the glycoside rather than being stripped to its aglycone apigenin ^{4Reference 4Jiao L et al. · 2017AnimalDegradation kinetics of 6'''-p-coumaroylspinosin and identification of its metabolites by rat intestinal floraView study →}. The point is visible in the jujube chemistry: gut flora remove the outer, O-linked sugars from spinosin (2”-O-glucosyl swertisin) and its coumaroyl esters to yield swertisin — and there the deglycosylation stops, because the remaining glucose is C-attached ^{4Reference 4Jiao L et al. · 2017AnimalDegradation kinetics of 6'''-p-coumaroylspinosin and identification of its metabolites by rat intestinal floraView study →}.

Practically, this makes swertisin its own circulating species with its own (poorly measured) pharmacokinetics, rather than a pro-drug for apigenin. It is also why C-glycosyl flavones as a class are studied as antidiabetic agents in their own right, not merely as aglycone carriers.

What It's Used For

The evidence is preclinical throughout, and it is worth separating the one genuinely distinctive thread — islet regeneration — from the more generic flavonoid activities.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. Every row here is preclinical; read the per-row basis.

01Islet Neogenesis and Beta-Cell RegenerationPromising46%Multiple in-vitro + rodent studies of the isolate; defined p38-SMAD mechanism ^{1,2,3Reference 1Dadheech N et al. · 2015Swertisin an anti-diabetic compound facilitate islet neogenesis from pancreatic stem/progenitor cells via p-38 MAP kinase-SMAD pathway: an in-vitro and in-vivo studyView study →Reference 2Srivastava A et al. · 2018AnimalSwertisin ameliorates diabetes by triggering pancreatic progenitors for islet neogenesis in streptozotocin treated BALB/c miceView study →Reference 3Srivastava A et al. · 2019AnimalPancreatic resident endocrine progenitors demonstrate high islet neogenic fidelity and committed homing towards diabetic mice pancreasView study →}

02Glucose Lowering and Enzyme InhibitionShaky38%Rodent + in-vitro; α-amylase inhibition and glucose uptake, partly via extract fractions ^{5,6,7Reference 5Sadeghi M et al. · 2022In vitroInhibitory effect of flavonoid glycosides on digestive enzymes: in silico, in vitro, and in vivo studiesView study →Reference 6Mokashi P et al. · 2017AnimalSwertisin rich fraction from Enicostema littorale ameliorates hyperglycemia and hyperlipidemia in high-fat fed diet and low dose streptozotacin induced type 2 diabetes mellitus in ratsView study →Reference 7Mokashi P et al. · 2017Flavonoids from Enicostema littorale blume enhances glucose uptake of cells in insulin resistant human liver cancer (HepG2) cell line via IRS-1/PI3K/Akt pathwayView study →}

03Neurocognitive EffectsShaky32%Rodent isolate; adenosine A1 antagonism and Akt–GSK-3β signalling ^{8,9Reference 8Lee S et al. · 2016AnimalSwertisin, a C-glucosylflavone, ameliorates scopolamine-induced memory impairment in mice with its adenosine A1 receptor antagonistic propertyView study →Reference 9Oh HK et al. · 2017AnimalSwertisin ameliorates pre-pulse inhibition deficits and cognitive impairment induced by MK-801 in miceView study →}

04Antiviral and Anti-InflammatoryShaky24%In-vitro + one transgenic-mouse anti-HBV study; TNF-α from an extract ^{10,11Reference 10Xu HY et al. · 2020Anti-hepatitis B virus activity of swertisin isolated from Iris tectorum MaximView study →Reference 11Garcia Ede F et al. · 2016In vitroIn vitro TNF-α inhibition elicited by extracts from Echinodorus grandiflorus leavesView study →}

Mechanisms

The load-bearing point is the top row: unlike most flavonoids studied only as antioxidants, swertisin’s headline claim is an active differentiation/regeneration mechanism — but it is defined entirely in cells and rodents.

Pharmacokinetics

Swertisin’s human pharmacokinetics are essentially uncharacterised. As a C-glycoside, it is expected to resist glycosidase hydrolysis and circulate intact rather than being cleaved to apigenin ^{4Reference 4Jiao L et al. · 2017AnimalDegradation kinetics of 6'''-p-coumaroylspinosin and identification of its metabolites by rat intestinal floraView study →} — but flavone C-glycosides as a class (and swertisin’s parent glycoside spinosin in particular) are noted for poor oral bioavailability, which is the main brake on translating the rodent antidiabetic data ^{12Reference 12Kuang X et al. · 2022ReviewThe pharmacology, pharmacokinetics, and toxicity of spinosin: a mini reviewView study →}. A rat study established an HPLC-MS/MS assay for swertisin after intravenous dosing, but published oral bioavailability, half-life and clearance figures for the molecule are lacking ^{13Reference 13Li Y et al. · 2017AnimalPharmacokinetic study of swertisin by HPLC-MS/MS after intravenous administration in ratsView study →}.

No reliable oral bioavailability number exists for swertisin — a real hole, given that all the efficacy data are oral-dose rodent studies.

Clinical Trials

There are no human clinical trials of isolated swertisin. Human exposure is indirect, through whole bitter herbs (Swertia, Enicostemma) and jujube-seed preparations, in which swertisin is one minor constituent among many.

Last checked: July 2026.

Isolate vs. Plant Studies

The evidence base is unusually isolate-weighted for a molecule with no human data — a genuine strength on one axis and a caution on another. The marquee islet-neogenesis findings ^{1,2,3Reference 1Dadheech N et al. · 2015Swertisin an anti-diabetic compound facilitate islet neogenesis from pancreatic stem/progenitor cells via p-38 MAP kinase-SMAD pathway: an in-vitro and in-vivo studyView study →Reference 2Srivastava A et al. · 2018AnimalSwertisin ameliorates diabetes by triggering pancreatic progenitors for islet neogenesis in streptozotocin treated BALB/c miceView study →Reference 3Srivastava A et al. · 2019AnimalPancreatic resident endocrine progenitors demonstrate high islet neogenic fidelity and committed homing towards diabetic mice pancreasView study →} and the α-amylase and neurocognitive studies ^{5,8,9Reference 5Sadeghi M et al. · 2022In vitroInhibitory effect of flavonoid glycosides on digestive enzymes: in silico, in vitro, and in vivo studiesView study →Reference 8Lee S et al. · 2016AnimalSwertisin, a C-glucosylflavone, ameliorates scopolamine-induced memory impairment in mice with its adenosine A1 receptor antagonistic propertyView study →Reference 9Oh HK et al. · 2017AnimalSwertisin ameliorates pre-pulse inhibition deficits and cognitive impairment induced by MK-801 in miceView study →} used purified swertisin, so the activity is attributable to the molecule rather than an unresolved mixture. But the metabolic whole-body work is often done with a swertisin-rich fraction of Enicostemma littorale ^{6,7Reference 6Mokashi P et al. · 2017AnimalSwertisin rich fraction from Enicostema littorale ameliorates hyperglycemia and hyperlipidemia in high-fat fed diet and low dose streptozotacin induced type 2 diabetes mellitus in ratsView study →Reference 7Mokashi P et al. · 2017Flavonoids from Enicostema littorale blume enhances glucose uptake of cells in insulin resistant human liver cancer (HepG2) cell line via IRS-1/PI3K/Akt pathwayView study →} rather than the pure compound, and the anti-inflammatory reading comes from a whole extract ^{11Reference 11Garcia Ede F et al. · 2016In vitroIn vitro TNF-α inhibition elicited by extracts from Echinodorus grandiflorus leavesView study →} — so the transfer from “swertisin-containing plant” to “swertisin the drug” is only partly established. No study bridges the two with a pharmacokinetic account of achievable exposure.

Prevalence in Nature

Swertisin is distributed across several unrelated plant families, always as a minor-to-moderate flavone C-glycoside rather than a dominant constituent, and clean quantitative figures are rarely published. It is best known from the Gentianaceae — Swertia (from which it is named) and Enicostemma littorale ^{6Reference 6Mokashi P et al. · 2017AnimalSwertisin rich fraction from Enicostema littorale ameliorates hyperglycemia and hyperlipidemia in high-fat fed diet and low dose streptozotacin induced type 2 diabetes mellitus in ratsView study →} — where it co-occurs with the bitter secoiridoid swertiamarin. It is a characteristic flavone C-glycoside of jujube / sour-date seed (Ziziphus jujuba var. spinosa), where it sits alongside its own glucoside spinosin ^{4Reference 4Jiao L et al. · 2017AnimalDegradation kinetics of 6'''-p-coumaroylspinosin and identification of its metabolites by rat intestinal floraView study →}. It has also been isolated from roof iris (Iris tectorum) ^{10Reference 10Xu HY et al. · 2020Anti-hepatitis B virus activity of swertisin isolated from Iris tectorum MaximView study →}, Gentiana species, Scorzonera, Desmodium caudatum and Echinodorus grandiflorus ^{11Reference 11Garcia Ede F et al. · 2016In vitroIn vitro TNF-α inhibition elicited by extracts from Echinodorus grandiflorus leavesView study →}.

Because reported occurrences are qualitative isolations rather than assayed concentrations, there is no reliable ranking of richest sources — quantifying swertisin content by plant and part is an open gap.

Discovery & Synthesis

Swertisin was characterised from Swertia japonica (Gentianaceae), the genus that gives it its name, and is registered as CAS 6991-10-2. Structurally it is 6-C-glucosyl-7-O-methylapigenin — equivalently, the 7-O-methyl ether of isovitexin, or genkwanin 6-C-glucoside — placing it firmly in the C-glucosylflavone family with vitexin and orientin.

Total synthesis is not well documented for swertisin; unlike many flavonoids it is not a routine synthetic target, and commercial and research material is obtained by extraction from plant sources (or, in principle, by regioselective 7-O-methylation of isovitexin). Manufacture today is therefore extraction-based, at reference-standard rather than bulk scale.

Patents: not yet researched.

Toxicity & Safety

Swertisin carries a low toxicity flag. It is a naturally occurring dietary flavone C-glycoside found in edible/medicinal plants (jujube seed, bitter Gentianaceae tonics) with a long history of indirect human consumption, and one extract-based genotoxicity screen reported the swertisin-containing fraction negative in a bacterial assay ^{14Reference 14Lima-Dellamora EC et al. · 2014Genotoxic Maillard byproducts in current phytopharmaceutical preparations of Echinodorus grandiflorusView study →}. No signal of acute toxicity emerged in the rodent efficacy studies at the doses used.

The flag is low, not none, because the safety base is thin rather than reassuring: there is no dedicated toxicology package for the isolated molecule — no repeat-dose, reproductive/developmental, or human safety data — and no characterised drug-interaction profile.

Safety at a Glance

✅ Low / no toxicity

• Low apparent toxicity. A dietary flavone C-glycoside from edible/medicinal plants; no acute toxicity noted in rodent efficacy studies, and an extract fraction tested negative for genotoxicity.
• No human safety data. Swertisin has never been given to people as a purified compound; safety is inferred from whole-plant use, not measured for the isolate.
• Untested interactions and no repeat-dose toxicology. No dedicated genotoxicity, reproductive/developmental or drug-interaction studies of the pure molecule exist; absence of findings is not evidence of safety.

Dosage

There is no established human dose for isolated swertisin — it has never been used as a purified drug in people. The figures in the literature are preclinical rodent doses (broadly ~10–50 mg/kg, e.g. 30 mg/kg in the cognitive studies) ^{8,9Reference 8Lee S et al. · 2016AnimalSwertisin, a C-glucosylflavone, ameliorates scopolamine-induced memory impairment in mice with its adenosine A1 receptor antagonistic propertyView study →Reference 9Oh HK et al. · 2017AnimalSwertisin ameliorates pre-pulse inhibition deficits and cognitive impairment induced by MK-801 in miceView study →}, and even these are hard to translate given that swertisin’s oral bioavailability is unmeasured ^{12,13Reference 12Kuang X et al. · 2022ReviewThe pharmacology, pharmacokinetics, and toxicity of spinosin: a mini reviewView study →Reference 13Li Y et al. · 2017AnimalPharmacokinetic study of swertisin by HPLC-MS/MS after intravenous administration in ratsView study →}.

Real-world human exposure is indirect and unquantified: swertisin is a minor flavone C-glycoside within whole bitter herbs such as chirata (Swertia) and Enicostemma, taken as bitter tonics, and within jujube-seed preparations used for sleep. These are doses studied in research and are not a personal recommendation.

References

1. Dadheech N, Srivastava A, Paranjape N, et al. (2015). Swertisin an anti-diabetic compound facilitate islet neogenesis from pancreatic stem/progenitor cells via p-38 MAP kinase-SMAD pathway: an in-vitro and in-vivo study. PLOS ONE. https://pubmed.ncbi.nlm.nih.gov/26047129/
2. Srivastava A, Dadheech N, Vakani M, Gupta S (2018). Swertisin ameliorates diabetes by triggering pancreatic progenitors for islet neogenesis in streptozotocin treated BALB/c mice. Biomedicine & Pharmacotherapy. https://pubmed.ncbi.nlm.nih.gov/29428671/
3. Srivastava A, Dadheech N, Vakani M, et al. (2019). Pancreatic resident endocrine progenitors demonstrate high islet neogenic fidelity and committed homing towards diabetic mice pancreas. Journal of Cellular Physiology. https://pubmed.ncbi.nlm.nih.gov/30341903/
4. Jiao L, Li Y, Zhang Y, et al. (2017). Degradation kinetics of 6'''-p-coumaroylspinosin and identification of its metabolites by rat intestinal flora. Journal of Agricultural and Food Chemistry. https://pubmed.ncbi.nlm.nih.gov/28513155/
5. Sadeghi M, Miroliaei M, Ghanadian M, et al. (2022). Inhibitory effect of flavonoid glycosides on digestive enzymes: in silico, in vitro, and in vivo studies. International Journal of Biological Macromolecules. https://pubmed.ncbi.nlm.nih.gov/35843397/
6. Mokashi P, Khanna A, Pandita N (2017). Swertisin rich fraction from Enicostema littorale ameliorates hyperglycemia and hyperlipidemia in high-fat fed diet and low dose streptozotacin induced type 2 diabetes mellitus in rats. Biomedicine & Pharmacotherapy. https://pubmed.ncbi.nlm.nih.gov/29031588/
7. Mokashi P, Khanna A, Pandita N (2017). Flavonoids from Enicostema littorale blume enhances glucose uptake of cells in insulin resistant human liver cancer (HepG2) cell line via IRS-1/PI3K/Akt pathway. Biomedicine & Pharmacotherapy. https://pubmed.ncbi.nlm.nih.gov/28364599/
8. Lee S, Kim J, Jeon SJ, et al. (2016). Swertisin, a C-glucosylflavone, ameliorates scopolamine-induced memory impairment in mice with its adenosine A1 receptor antagonistic property. Behavioural Brain Research. https://pubmed.ncbi.nlm.nih.gov/26996316/
9. Oh HK, Jeon SJ, Lee S, et al. (2017). Swertisin ameliorates pre-pulse inhibition deficits and cognitive impairment induced by MK-801 in mice. Journal of Psychopharmacology. https://pubmed.ncbi.nlm.nih.gov/27729563/
10. Xu HY, Ren JH, Su Y, et al. (2020). Anti-hepatitis B virus activity of swertisin isolated from Iris tectorum Maxim. Journal of Ethnopharmacology. https://pubmed.ncbi.nlm.nih.gov/32224198/
11. Garcia Ede F, de Oliveira MA, Dourado LP, et al. (2016). In vitro TNF-α inhibition elicited by extracts from Echinodorus grandiflorus leaves. Planta Medica. https://pubmed.ncbi.nlm.nih.gov/26692456/
12. Kuang X, She G, Ma T, et al. (2022). The pharmacology, pharmacokinetics, and toxicity of spinosin: a mini review. Frontiers in Pharmacology. (Spinosin is 2”-O-glucosyl swertisin; the review notes poor oral bioavailability limits its clinical use.) https://pubmed.ncbi.nlm.nih.gov/36193419/
13. Li Y, Zhao X, Zhang Y, et al. (2017). Pharmacokinetic study of swertisin by HPLC-MS/MS after intravenous administration in rats. Journal of Chromatographic Science. https://pubmed.ncbi.nlm.nih.gov/27993862/
14. Lima-Dellamora EC, Waldhelm KC, et al. (2014). Genotoxic Maillard byproducts in current phytopharmaceutical preparations of Echinodorus grandiflorus. Anais da Academia Brasileira de Ciências. https://pubmed.ncbi.nlm.nih.gov/25098311/

View all 14 references▾